financetom
Business
financetom
/
Business
/
Merck Say Lung Cancer Treatment Receives FDA Breakthrough Therapy Designation
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Merck Say Lung Cancer Treatment Receives FDA Breakthrough Therapy Designation
Dec 3, 2024 5:26 AM

07:55 AM EST, 12/03/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday the US Food and Drug Administration has granted breakthrough therapy designation to sacituzumab tirumotecan, a treatment for certain times of non-small cell lung cancer.

The designation is based on data from the phase 2 expansion group of a phase 1/2 study, as well as data from two parts of a phase 2 study evaluating the treatment in patients who have received at least two lines of previous therapy, Merck ( MRK ) said.

Sacituzumab tirumotecan is being developed in partnership with Kelun-Biotech, Merck ( MRK ) said.

Merck ( MRK ) shares were 0.4% higher in premarket trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved